|
Synonyms: OMP-21M18 | OMP21M18
Compound class:
Antibody
Comment: Demcizumab is a humanised IgG2 monoclonal antibody targeting DLL4 (delta like canonical Notch ligand 4), a membrane bound Notch receptor ligand expressed predominantly on vascular endothelial cells.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. A BLAST search using the peptide sequence of the variable region of the heavy chain forming demcizumab reveals US7750124 B2 as the covering patent [2]. |
| Bioactivity Comments |
| The binding affinity presented in the table below is the only one provided in the covering patent, and is for the humanised 21M18 variant H2L2 [2]. It is unclear which variant went on to become demcizumab. |
| Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
